Top

Published in:

01-06-2010 | Original Article

Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment

Authors: Siavash Piran, Dominick Amato

Published in: Journal of Inherited Metabolic Disease | Issue 3/2010

Abstract

Type 1 Gaucher disease (GD1) is an inherited lysosomal storage disease, which is often managed by enzyme replacement therapy (ERT). The bone response to ERT is usually slower than visceral and hematological responses. There is uncertainty as to whether an increase in the dosage of ERT has a beneficial effect. The aim of our study was to determine whether or not there is sufficient evidence to make a definitive statement about the effects of ERT and substrate reduction therapy (SRT) on bone marrow infiltration and bone mineral density (BMD) in GD1. We conducted a systematic review of all studies examining the effects of ERT and SRT on bony complications of GD1 published before July 2008. The studies were identified by a computerized search with use of Medline, Embase, The Cochrane Database of Systematic Reviews, The Cochrane Central Register of Controlled Trials (CCTR), and bibliographies of papers subsequently retrieved from the search. Three hundred studies were grouped according to whether they deal with the natural history of GD1 or therapeutic issues, and 17 studies were included in the review. The results from our systematic review suggest that further investigations, such as better analysis of the Gaucher Registry, are needed on the effects of ERT and SRT on bony complications of GD1. Studies on the effects of the newly identified velaglucerase and the plant-derived glucocerebrosidase on bony complications of GD1 are also needed.

Arnheim E, Chicco G, Phillips M et al (2008) Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density. Rheumatol Int 28(9):873–877CrossRefPubMed

Beutler E, Demina A, Laubscher K et al (1995) The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 21:86–108CrossRefPubMed

Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71:205–211CrossRefPubMed

Chen M, Wang J (2008) Gaucher disease: review of the literature. Arch Pathol Lab Med 132:851–853PubMed

Ciana G, Addobbati R, Tamaro G et al (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28:723–732CrossRefPubMed

Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481–1485CrossRefPubMed

Curtin F, Altman DG, Elbourne D (2002) Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med 21(15):2131–2144CrossRefPubMed

de Fost M, Hollak CE, Groener JE et al (2006) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108:830–835CrossRefPubMed

de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE (2008) Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93:1119–1120CrossRefPubMed

Elstein D, Zimran A (2009) Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 3:407–417PubMed

Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A (1998) Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM 91:483–488CrossRefPubMed

Elstein D, Hollak C, Aerts JM et al (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757–766CrossRefPubMed

Elstein D, Dweck A, Attias D et al (2007) Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 110:2296–2301CrossRefPubMed

El-Beshlawy A, Ragab L, Youssry I et al (2006) Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29:92–98CrossRefPubMed

Giraldo P, Latre P, Alfonso P et al (2006) Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher’s disease. Haematologica 91:703–706PubMed

Grabowski GA, Barton NW, Pastores G et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122:33–39PubMed

Grabowski GA, Leslie N, Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 12:115–133CrossRefPubMed

Guggenbuhl P, Grosbois B, Chalès G (2008) Gaucher disease. Joint Bone Spine 75:116–124CrossRefPubMed

Hollak CE, Aerts JM, Goudsmit R et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 345:1474–1478CrossRefPubMed

Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27:1005–1012CrossRefPubMed

Hůlková H, Ledvinová J, Poupetová H, Kohout A, Malinová V, Elleder M (2009) Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process. J Inherit Metab Dis 32(4):551–559CrossRefPubMed

Johnson LA, Hoppel BE, Gerard EL et al (1992) Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182(2):451–455PubMed

Lebel E, Dweck A, Foldes AJ et al (2004) Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 22:597–601CrossRefPubMed

Maas M, Poll LW, Terk MR (2002a) Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 75(1):A13–A24PubMed

Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ (2002b) Quantification of skeletal involvement in adults with type I Gaucher’s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179(4):961–965PubMed

Maas M, van Kuijk C, Stoker J et al (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging–initial experience. Radiology 229:554–561CrossRefPubMed

Mikosch P, Reed M, Baker R et al (2008) Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with Imiglucerase and Miglustat. Calcif Tissue Int 83(1):43–54CrossRefPubMed

Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ (2009) Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 147(4):561–570CrossRefPubMed

Olsen E, McHugh K, Vellodi A (2003) Routine magnetic resonance imaging of the spine in children with Gaucher disease: does it help therapeutic management? Pediatr Radiol 33:782–785CrossRef

Parisi MS, Mastaglia SR, Bagur A, Goldstein G, Zeni SN, Oliveri B (2008) Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. Eur J Med Res 13(1):31–38PubMed

Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82:408–416PubMed

Pastores GM, Barnett NL, Kolodny EH et al (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215–1227CrossRefPubMed

Pastores GM, Elstein D, Hrebícek M, Zimran A (2007) Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 29:1645–1654CrossRefPubMed

Poll LW, Koch JA, vom Dahl S et al (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 30:496–503CrossRefPubMed

Poll LW, Koch JA, Willers R et al (2002) Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 28:209–220CrossRefPubMed

Robertson PL, Maas M, Goldblatt J (2007) Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. AJR Am J Roentgenol 188:1521–1528CrossRefPubMed

Roca M, Mota J, Alfonso P, Pocoví M, Giraldo P (2007) S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol 62(1):132–137CrossRefPubMed

Rosenthal DI, Doppelt SH, Mankin HJ et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96:629–637PubMed

Schiffmann R, Mankin H, Dambrosia JM et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28(2):288–296CrossRefPubMed

Sims KB, Pastores GM, Weinreb NJ et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73:430–440CrossRefPubMed

Terk MR, Dardashti S, Liebman HA (2000) Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 29:563–571CrossRefPubMed

van Rijn RR, van der Sluis IM, Link TM et al (2003) Bone densitometry in children: a critical appraisal. Eur Radiol 13(4):700–710PubMed

Weinreb NJ, Cappellini MD, Cox TM et al (2010) A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med 12(1):44–51CrossRefPubMed

Wenstrup RJ, Kacena KA, Kaplan P et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22:119–126CrossRefPubMed

Wilson C, Spearing R, Teague L, Robertson P, Blacklock H (2007) The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy. Mol Genet Metab 92:131–136CrossRefPubMed

Title: Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment
Authors: Siavash Piran
Dominick Amato
Publication date: 01-06-2010
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-010-9071-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Basal ganglia lesions in the early stage of Menkes disease

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

Hematopoiesis in the thymidine kinase 2 deficient mouse model of mitochondrial DNA depletion syndrome

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice

Lysosomal lipid vacuoles in macrophages located in the colon

High-resolution melting analysis, a simple and effective method for reliable mutation scanning and frequency studies in the ACADVL gene

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page